The FDA has approved Evrysdi in tablet form for patients with spinal muscular atrophy aged 2 years and older who weigh more ...
The FDA on Wednesday approved the industry’s first-ever tablet treatment for spinal muscular atrophy— Roche ’s SMN2 splicing ...
Market OverviewThe Orphan Drugs Market is a specialized sector within the pharmaceutical industry that focuses on the ...
The 5 mg risdiplam tablet provides the same efficacy and safety for spinal muscular atrophy as the currently available oral ...
The Muscular Dystrophy Association celebrates this new more accessible treatment option for people living with SMA. MDA - New ...
Infants with SMA type 1 born since 2016 experience better functional outcomes and life expectancy with disease-modifying treatments.
Spinraza treatment does not lead to significant kidney dysfunction in SMA patients with types 1 and 2, a safety and efficacy ...
Biotech giant Biogen Inc (NASDAQ:BIIB) is scheduled to report fourth-quarter earnings on 12 February. The Wall Street ...
Three people with a muscle-destroying disease destined to worsen got a little stronger when an implanted device zapped their ...
From February 12, all newborn babies will be offered screening for spinal muscular atrophy (SMA), a rare progressive neuromuscular disease. SMA will be one of more than 20 other rare disorders ...
From February 12, all newborn babies will be offered screening for spinal muscular atrophy (SMA), a rare progressive neuromuscular disease. SMA will be one of more than 20 other rare disorders ...
A Boston-area biopharmaceutical firm has submitted a biologics license application to the FDA for its investigational, fully ...